Cortical Labs CL3 Deep Dive: Living Neuron Computing Systems Blur the Line Between Biology and Silicon

Cortical Labs CL3 Deep Dive: Living Neuron Computing Systems Blur the Line Between Biology and Silicon

The CL3, the third-generation biocomputing chip released by Melbourne-based startup Cortical Labs in July 2028, signals that a new branch of computing architecture is moving from the laboratory toward engineering. Inside this chip, approximately 8 million human induced pluripotent stem cell-derived neurons are cultivated and fixed on a silicon substrate containing 26,000 electrodes, forming hybrid computing units with conventional CMOS circuits.

CL3 works fundamentally differently from pure silicon chips. When input signals are transmitted to the neuron networks through the electrode array, synaptic connections between neurons undergo plastic changes based on signal patterns—essentially, living tissue is "learning." Cortical Labs Chief Scientific Officer Brett Kagan explains: "Silicon chips excel at precise computation, but biological neurons have natural advantages in pattern recognition and adaptability. CL3's purpose is to let both play to their strengths."

In benchmark testing, CL3 excelled at incremental learning tasks in image classification. After being shown an object category it had never encountered, CL3 achieved 85% classification accuracy with only about 120 samples, while silicon-based neural networks of comparable scale typically require over 2,000 samples. This data efficiency advantage is particularly pronounced in data-scarce scenarios like rare medical image analysis or industrial anomaly detection.

But CL3's core challenge is ethical rather than technical. Using human neurons for computation has sparked intense debate. The UK Nuffield Council on Bioethics noted in its July report that whether cultivated neuron networks could develop some form of consciousness is "a question that cannot currently be answered with certainty." The report recommends continuous monitoring of CL3-type systems and establishing consciousness indicator thresholds for neuron network activity.

Cortical Labs currently uses induced pluripotent stem cells reprogrammed from voluntary donors' skin cells, which are then differentiated into neurons. The company says all donors signed detailed informed consent forms and cell sources are fully traceable. But ethicist Nancy Chen points out: "Informed consent cannot cover future uses that donors cannot foresee. When these neurons are used in commercial products, how should donors' 'contribution' to these cells be treated?"

On the commercial side, Cortical Labs has signed cooperation agreements with three pharmaceutical companies to use CL3 for in vitro neurotoxicity testing in drug screening. Compared to traditional animal experiments, human neuron networks can more accurately predict drugs' effects on the human nervous system.